Literature DB >> 20428857

The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances.

Daniella G Batista1, Kátia R Neves, Fabiana G Graciolli, Luciene M dos Reis, Rafael G Graciolli, Wagner V Dominguez, Carolina L Neves, Andrea O Magalhães, Melani R Custódio, Rosa M Moysés, Vanda Jorgetti.   

Abstract

Bone disease is a common disorder of bone remodeling and mineral metabolism, which affects patients with chronic kidney disease. Minor changes in the serum level of a given mineral can trigger compensatory mechanisms, making it difficult to evaluate the role of mineral disturbances in isolation. The objective of this study was to determine the isolated effects that phosphate and parathyroid hormone (PTH) have on bone tissue in rats. Male Wistar rats were subjected to parathyroidectomy and 5/6 nephrectomy or were sham-operated. Rats were fed diets in which the phosphate content was low, normal, or high. Some rats received infusion of PTH at a physiological rate, some received infusion of PTH at a supraphysiological rate, and some received infusion of vehicle only. All nephrectomized rats developed moderate renal failure. High phosphate intake decreased bone volume, and this effect was more pronounced in animals with dietary phosphate overload that received PTH infusion at a physiological rate. Phosphate overload induced hyperphosphatemia, hypocalcemia, and changes in bone microarchitecture. PTH at a supraphysiological rate minimized the phosphate-induced osteopenia. These data indicate that the management of uremia requires proper control of dietary phosphate, together with PTH adjustment, in order to ensure adequate bone remodeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428857     DOI: 10.1007/s00223-010-9367-y

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  5 in total

1.  Effect of variations in dietary Pi intake on intestinal Pi transporters (NaPi-IIb, PiT-1, and PiT-2) and phosphate-regulating factors (PTH, FGF-23, and MEPE).

Authors:  Tatiana Martins Aniteli; Flávia Ramos de Siqueira; Luciene Machado Dos Reis; Wagner Vasques Dominguez; Elizabeth Maria Costa de Oliveira; Patrícia Castelucci; Rosa Maria Affonso Moysés; Vanda Jorgetti
Journal:  Pflugers Arch       Date:  2018-01-25       Impact factor: 3.657

2.  Therapeutic efficacy of two surgical methods on the secondary hyperparathyroidism.

Authors:  Chao Gu; Zhenyu Ye; Yanan Wang; Qin Wang; Jie Qi; Jianhua Chen; Shan Chen; Zekuan Xu
Journal:  Gland Surg       Date:  2020-04

3.  The vitamin D, ionised calcium and parathyroid hormone axis of cerebral capillary function: therapeutic considerations for vascular-based neurodegenerative disorders.

Authors:  Virginie Lam; Ryusuke Takechi; Menuka Pallabage-Gamarallage; Corey Giles; John C L Mamo
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 4.  Recent advances in the noninvasive diagnosis of renal osteodystrophy.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Kidney Int       Date:  2013-06-26       Impact factor: 10.612

5.  Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

Authors:  Juliana C Ferreira; Guaraciaba O Ferrari; Katia R Neves; Raquel T Cavallari; Wagner V Dominguez; Luciene M Dos Reis; Fabiana G Graciolli; Elizabeth C Oliveira; Shiguang Liu; Yves Sabbagh; Vanda Jorgetti; Susan Schiavi; Rosa M A Moysés
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.